With the positive CHMP opinion after the Q3 report, the quarterly results were a non-event. Leqembi can now be launched in the first markets in Europe in H1 2025. On the development side, BioArctic highlighted the pre-clinical data on its Brain Transporter (BT) technology, which showed the mechanism significantly increases the transport of large molecules (mAbs) across the blood brain barrier (BBB). We reiterate our BUY and have raised our target price to SEK350 (270), adding the EU market oppor...
Seven Directors at Ambea AB sold/sold after exercising options 131,142 shares at between 97.000SEK and 99.500SEK. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
This week, Hufvudstaden, Veidekke, Selvaag Bolig and Skanska reported Q3 results. Furthermore, Vasakronan (unlisted) reported soft vacancies and net lettings, which we consider a negative datapoint for peers such as Fabege and Hufuvdstaden. The weighted-average implied EBITDA yields on the stocks we cover are 4.33% for 2024e and 4.88% for 2025e.
Q3 showed continued solid revenue, earnings and FCF generation, with Ambea close to reaching its medium-term >9.5% EBITA margin target (Q3 LTM 9.4%). We see a strong case, given: 1) the robust demand outlook combined with an asset-light, cash-generating model; 2) renewed execution on bolt-on acquisitions and dividends/share buybacks; and 3) an attractive valuation at 2024–2026e FCF yields of 9–11%. We reiterate our BUY and have raised our target price to SEK120 (110).
This week, we upgraded Balder to BUY and Sagax to HOLD following their Q3 results, Balder completed a SEK1.5bn equity raise and bought assets from a JV, while a >5% rent increase for 2025 provided a positive datapoint for rent-regulated apartments in Sweden. The weighted-average implied EBITDA yields on the stocks we cover are 4.31% for 2024e and 4.86% for 2025e.
Q1 was in line with our forecasts, showing growth across all segments. We see a solid demand outlook, driving growth, and an attractive valuation (2024/25–2026/27e FCF yield of 15–20%), with AcadeMedia back in acquisition mode (four bolt-ons in Q1) and the now recurring share redemption programme (SEK300m) addressing its weak track record in capital allocation. We see the potential for a continued re-rating and reiterate our BUY and SEK92 target price.
This week, reporting season was in full swing, with nine covered companies reporting Q3 results. Overall, the results were mixed, while net lettings and vacancy rates were main points of interest given the current weak rental markets. The weighted-average implied EBITDA yields on the stocks we cover are 4.32% for 2024e and 4.78% for 2025e.
This week, we shifted our coverage from KCM Properties to Logistea and reinstated a recommendation with a BUY and SEK20 target price. In other news, Entra reported soft Q3 results, while Atrium Ljungberg’s were more neutral, and we see a potential catalyst for the Swedish residential market at the start of November. The weighted-average implied EBITDA yields on the stocks we cover are 4.70% for 2024e and 5.17% for 2025e.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.